What Clario does

Clario is a clinical trial endpoint technology company that provides data and technology solutions for drug and medical device approvals across pharmaceutical, biotechnology, and Contract Research Organization (CRO) customers. Formed in 2021 through the merger of ERT (eResearchTechnology) and Bioclinica, the company operates a cloud-native integrated platform spanning six core product lines: Cardiac Solutions (ECG, arrhythmia, blood pressure, Phase I/TQT assessment); eCOA (electronic clinical outcome assessments including neuroscience, oncology, rater training, and the eC-SSRS for suicidal ideation monitoring); Medical Imaging (centralized core lab with AI-powered redaction and SMART Submit); Precision Motion (Opal V2R/V2C wearable sensors for digital mobility endpoints); Respiratory Solutions (SpiroSphere, home spirometry, oscillometry); and Clinical Adjudication (centralized endpoint committee platform with 15,000+ active users across 61 countries). The platform is supported by Trial Enablement software and AI Solutions with 120+ proprietary AI models deployed across 600+ active trials. Notable proprietary technologies include the FDA-cleared SpiroSphere with wireless ECG, the EPQT (Early Precision QT) methodology enabling potential TQT waiver qualification, and Opal sensors capable of predicting fall risk in Parkinson's patients with 84-92% accuracy.

Clario's go-to-market is enterprise field sales targeting pharmaceutical sponsors, biotech companies, and CROs globally, with study-by-study pricing that scales with therapeutic area, endpoints, geographies, languages, patient volume, and study duration. Sales cycles are long and technically complex, requiring deep scientific and regulatory expertise. The company has supported over 30,000 clinical trials across more than 100 countries with translations in over 100 languages, contributing to approximately 70% of FDA and EMA novel drug approvals since 2015 (700+ approvals). It maintains 70,000+ active trial sites, ships 136,000 validated devices per year through logistics hubs in the US, EU, and Japan, and has engaged 2.8 million+ patients through its eCOA Rapid Start catalog and 500,000+ patients in eCOA neuroscience trials.

Revenue derives primarily from clinical trial endpoint services billed study-by-study under multi-year enterprise agreements, supplemented by technology licensing and platform access. 2025 revenue was projected at approximately $1.25 billion prior to Clario's acquisition by Thermo Fisher Scientific, completed in March 2026 for $8.875 billion in cash plus up to $525 million in earnout payments — representing an exit for private equity sponsors Astorg, Cinven, Nordic Capital, and Novo Holdings. Post-acquisition, Clario operates as a subsidiary within Thermo Fisher's clinical research services segment.

Name

Clario

Legal name

Clario

Website

https://clario.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Clario is a clinical trial endpoint technology company providing cloud-native eCOA, cardiac safety, medical imaging, precision motion, and respiratory solutions to pharmaceutical, biotech, and CRO sponsors across 100+ countries, supporting 70% of FDA/EMA novel drug approvals since 2015.

Ownership category

akta.pro rank

Product category

Clinical Trial Endpoint Technology

NAICS

Computer Systems Design and Related Services (54151), Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Prepackaged Software (7372), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Clinical trial endpoints
• Cardiac safety monitoring
• Electronic clinical outcomes
• Medical imaging core lab
• Clinical trial technology

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Trial Endpoint Solutions: Clario generates revenue by providing endpoint data solutions to pharmaceutical and biotech companies conducting clinical trials. Services are priced study-by-study based on complexity, scope, geographic reach, and duration. Revenue projected at approximately $1.25 billion in 2025 prior to acquisition by Thermo Fisher.
2. Technology Licensing and Platform Access: Revenue from licensing proprietary technology platforms, AI models, and specialized assessment tools to clinical trial sponsors and CROs.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Clario provides technology-enabled endpoint data solutions for clinical trials that collect, process, and analyze data used to support drug and medical device approvals. Its offerings span six core endpoint categories: Cardiac Solutions (centralized ECG, arrhythmia analysis, blood pressure, Phase I/TQT assessment), eCOA (electronic patient-, clinician-, and performance-reported outcomes including neuroscience modules), Medical Imaging (centralized imaging core lab with SMART Submit platform), Precision Motion (Opal® wearable sensors for mobility endpoints), Respiratory Solutions (spirometry, oscillometry, SpiroSphere® device), and Clinical Adjudication (centralized endpoint committee platform). Supporting capabilities include Trial Enablement software, Hybrid Trials services, and an AI platform with 120+ models, all delivered globally across 100+ countries.

Product overview

Clario is a clinical trial endpoint technology company offering a comprehensive platform of endpoint solutions for clinical trials. The portfolio includes six core products: Cardiac Solutions (ECG, arrhythmia, blood pressure monitoring with regulatory consulting), eCOA (electronic clinical outcome assessments including neuroscience, oncology, and specialized modules like Swift, Rapid Start, and training), Medical Imaging (centralized core lab services with SMART technology), Precision Motion (Opal® wearable sensors for mobility), Respiratory Solutions (spirometry, home testing, oscillometry), and Clinical Adjudication (centralized endpoint committee platform). Supporting capabilities include Trial Enablement software, AI Solutions (120+ models across 600+ trials), and Hybrid Trials services. The platform operates across 100+ countries in 100+ languages, supporting over 30,000 trials and approximately 70% of FDA and EMA new drug approvals since 2015.

Differentiator

Problem solved

Functional benefit

Brands

• eResearchTechnology (ERT): Legacy brand for cardiac safety solutions, part of Clario's portfolio
• Bioclinica
• Opal V2R
• Opal System
• SpiroSphere
• eC-SSRS
• SMART Submit
• Virgil Academy
• Virgil University
• SafePatient ECG

Products and services

• Cardiac Solutions Global-ready cardiac safety and efficacy endpoint solutions for all phases of clinical trials, including centralized ECG collection, arrhythmia analysis, blood pressure monitoring, and regulatory consulting. Supports more than 13,800 trials globally and more than 580 new drug approvals through cardiac solutions alone.
• eCOA (Electronic Clinical Outcome Assessment) Comprehensive electronic clinical outcome assessment platform supporting electronic patient-reported outcomes (ePRO), clinician-reported outcomes (eClinRO), and performance outcomes (ePerfO) across decentralized, hybrid, and site-based trials in 120+ countries.
• Medical Imaging World-leading centralized medical imaging core lab services for clinical trials with SMART technology suite processing images from electronic transfer through independent analysis. Supports more than 5,000 imaging studies across CT, MRI, endoscopy, and other modalities.
• Precision Motion Complete solution for measuring objective digital endpoints of mobility using Opal® wearable sensor technology, including Opal V2C® for clinical trials and Opal V2R® for research applications. Predictive of fall risk in Parkinson's patients with 84-92% accuracy up to two years in advance.
• Respiratory Solutions Comprehensive respiratory endpoint solutions generating high-quality pulmonary function data through site-based spirometry, virtual home spirometry, cough/lung sound assessment, DLCO, and oscillometry. Includes FDA-cleared SpiroSphere® device with wireless ECG.
• Clinical Adjudication Centralized, cloud-based clinical endpoint adjudication platform with real-time case routing, automated workflows, AI-driven redaction, and discordance detection. Supports 15,000+ active users across 61 countries.
• Trial Enablement Cloud-native technologies and clinical trial software for participant screening, data collection, cleaning, QC, and assessment including Eligibility Solution, Reporting & Analytics, and Source Document Manager.
• Artificial Intelligence (AI) Solutions AI-enabled clinical trial solutions including more than 120 AI models deployed across 600+ active trials. Capabilities span vocal biomarkers, Image Redact AI, AI-enabled spirometry insights, and Study Insight Analytics, certified to ISO 42001:2023.
• Hybrid Trials Endpoint technology and services for virtual or hybrid clinical trials combining on-site and remote data collection using connected devices and decentralized trial capabilities across 100+ countries.
• Suicidal Ideation Assessment (eC-SSRS) Electronic Columbia-Suicide Severity Rating Scale (C-SSRS) for monitoring suicidal ideation and behavior in clinical trials. Includes patient-reported ePRO and clinician-led eClinRO options with real-time alerts to clinicians; exclusive clinical trial licensing.
• Rater, Participant and Caregiver Training Comprehensive training solutions including PANSS rater training, placebo response reduction training, and participant/caregiver training. Trained 41k+ clinical site raters and 125k+ participants/caregivers, including 8 of top 10 biopharmaceutical companies utilizing rater training services.
• Phase I/TQT Cardiac Assessment (EPQT) Early Precision QT (EPQT) methodology for cost-effective QT assessments in Phase I studies, enabling earlier cardiac safety decisions and potential TQT waiver qualification under ICH E14 guidelines.
• eCOA Swift (Early Phase Oncology) Fast, cost-effective eCOA solution for early phase oncology trials with setup in as little as 2 weeks. Delivers near-real-time tolerability monitoring and 90%+ compliance rates.
• eCOA Rapid Start (Assessment Catalog) Pre-validated and configured eCOA assessments enabling trial setup from kick-off to UAT in as little as 6 weeks. Features 1,000+ pre-validated, version-controlled assessments with 2.8M+ patients engaged.

Quantifiable outcome

• 70% of FDA and EMA novel drug approvals since 2015 supported by Clario's platform
• +6 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability12 records

Feature7 records

Partnerships

Six partnerships are on record, tiered minor and core.

• University of Oxford (NeuroMetrology Lab)minorStrategic or Co-development Partner · 6 October 2025Collaboration to advance Parkinson's disease research using Clario's Opal wearable sensor system. First participant enrolled in study to validate fall risk prediction capabilities.
• WCG (eCOA Business)coreStrategic or Co-development Partner · 6 May 2025Clario completed acquisition of WCG's electronic clinical outcome assessment (eCOA) business, enhancing capabilities in neuroscience clinical trial data collection and analysis. The acquisition expanded expertise in neuroscience, psychiatry, and rare diseases.
• PathAIcoreTechnology or Integration · 17 March 2025Clario and PathAI announced collaboration to deliver an integrated solution for gastrointestinal (GI) clinical trials, combining Clario's endpoint expertise with PathAI's AI-powered pathology analysis.
• Mobilise-DminorStrategic or Co-development Partner · 13 August 2024Clario joined forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials, combining expertise in wearable sensors and mobility assessment.
• ArtiQcoreStrategic or Co-development Partner · 2 April 2024Clario acquired ArtiQ, an AI-powered software company specializing in respiratory solutions. The acquisition expanded Clario's respiratory solutions portfolio and AI capabilities for respiratory testing, enhancing quality and efficiency of clinical trial data analysis.
• NeuroRxcoreStrategic or Co-development Partner · 17 March 2024Clario acquired NeuroRx, an imaging analysis provider specializing in neurological therapies including multiple sclerosis. This strengthened Clario's capabilities in neuroscience imaging.

Scale indicators17 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Parexel: Parexel is a global CRO with endpoint, biostatistics, and clinical pharmacology services that overlap with Clario's Phase I/cardiac safety and statistical analysis offerings, particularly in early-phase and regulatory strategy engagements.
• IQVIA: IQVIA is the largest global CRO with embedded eClinical/endpoint technology capabilities. It competes with Clario on integrated endpoint delivery, particularly through its R&D Solutions segment, while also being a customer/channel for some endpoint services.
• ICON plc: ICON is a top-3 global CRO that delivers endpoint, imaging, and eCOA-adjacent services. It is both a competitor for integrated trial delivery and a customer of endpoint technology.
• Oracle Health Sciences (Clinical One): Oracle's Clinical One platform offers unified EDC, RTSM, and eCOA capabilities that compete with Clario's endpoint platform, particularly for large Phase III programs and sponsors standardizing on Oracle infrastructure.

Direct peers

• BioTelemetry (Philips): BioTelemetry, acquired by Philips, provides cardiac monitoring services including MCT and Holter for clinical trials, directly competing with Clario's Cardiac Solutions portfolio (arrhythmia, ECG, ambulatory BP).
• Signant Health: Signant Health (formerly CRF Health and Bracket) provides eCOA, rater training, and clinical supply solutions, directly competing with Clario's eCOA and neuroscience offerings for CNS and rare disease trials.
• Veeva Systems: Veeva's Vault CTMS, Vault EDC, and Vault CDB compete directly with Clario's trial enablement and clinical data infrastructure offerings. Veeva's life-sciences cloud software stack overlaps Clario's enterprise SaaS GTM into pharma/biotech sponsors.
• Medidata Solutions (Dassault Systèmes): Medidata's Rave platform is a leading EDC/eCOA/Imaging/CTMS suite widely used in clinical trials. It is the closest direct competitor to Clario's eCOA and Trial Enablement offerings, with overlapping endpoints, customers (large pharma/biotech), and a comparable SaaS-style enterprise GTM.

Emerging players

• Medable: Medable focuses on decentralized clinical trial (DCT) platform technology, overlapping with Clario's hybrid trial, eCOA Live, and connected-device initiatives. Medable is a more focused emerging competitor in DCT enablement.
• Castor: Castor offers an eClinical platform (EDC, ePRO, eConsent) targeting academic and emerging biotech sponsors. It competes with Clario's eCOA and trial enablement offerings in the small-to-mid sponsor segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/clario
• LinkedInlinkedin.com/company/clario-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clario